Provided are a cold storage method and a cold storage liquid that are suitable for non-freezing refrigerated storage of human or animal stem cells such as iPS cells or embryos in a non-frozen state. According to an embodiment, the non-freezing refrigerated storage liquid is: a mixture liquid (HTM, HTMx2c13), in which MEM-alpha (Minimum Essential Medium Eagle (MEM) Alpha Modification) is mixed with a UW solution (UW_sln; BELZER UW (registered trademark) COLD STORAGE SOLUTION), or a modified UW solution (polymer component being changed to PVA), are mixed in a ratio of about 1/1 to 1/2; or a storage liquid having a composition equivalent to the mixture liquid, especially in respect of concentrations of potassium ions and sodium ions. And, arousal period(s) of maintaining a temperature of 30 C. to 37 C. is inserted at each of two to five days, into a non-freezing refrigerated storage period, which is made at 2 C. to 8 C. for 2 to 10 days or 4 to 20 days.

It is to provide a liquid for cryopreserving a cell that can effectively suppress cell death caused by freezing and thawing of a mammalian cell and that can effectively increase the proliferation ability of the mammalian cell after freezing and thawing, and a method for cryopreserving a mammalian cell using the liquid for cryopreserving a cell. A liquid comprising 2.5 to 8.75 (v/v) % propylene glycol is used as a liquid for cryopreserving a mammalian cell.

A method for in vitro expansion of cryopreserved cord blood-derived regulatory T cells (Tregs) with a high recovery rate is provided, including the following steps: recovering the cryopreserved cord blood-derived Tregs after first expansion, and resuspending the cells with a serum-free medium; and adding a resulting suspension to an expansion culture medium, and conducting a second expansion culture, where a primary culture is conducted for 1 d to 2 d, then a subculture is conducted once every 1 d to 3 d, and a total culture time is 13 d or more. In the expansion culture medium, interleukin-2 (IL-2) is further added. The method can achieve the second recovery and expansion of cryopreserved Tregs produced after the first expansion. Tregs produced after the second recovery and expansion can have a viability of 90% or more, and can be further expanded (such as third expansion and fourth expansion).

A dual-vial system, kit, and method for preservation of semen samples in mail-in semen analysis kits are described. The system comprises a dual-vial kit that comprises a first vial for collecting a semen sample of a subject, a second vial having a predetermined volume of a stabilization medium, and a transfer device for transferring a predetermined portion of the semen sample from the first vial to the second vial such that the transfer device has a volume allowing transfer of 1 part of the semen sample to be diluted in 3 parts of the stabilization medium in the second vial. Accordingly, the dual-vial kit enables preservation of semen viability for an extended period of up to 72 hours and carrying out of semen analysis within up to 72 hours of storing the semen in the stabilization medium.

Provided are methods and compositions for cryopreserving subpopulations of lymphocytes. In one aspect, provided herein is a method of generating a sub-population of lymphocytes from a biological sample, the method comprising cryopreserving said biological sample in a cryopreserving solvent comprising less than 2M molar concentration of an active cryopreserving moiety. In another aspect, provided herein is a cellular composition comprising an enhanced sub-population of lymphocytes, an enhanced second sub-population of lymphocytes, and a depleted third subpopulation of lymphocytes, wherein said cellular composition further comprises a cryopreserving solvent comprising less than 2M molar concentration of an active cryopreserving moiety. In another aspect, provided herein is a method for preparing an allogenic composition from a biological sample, wherein said allogenic composition comprises an enhanced sub-population of lymphocytes, the method comprising cryopreserving said biological sample in a cryopreserving solvent comprising less than 2M molar concentration of an active cryopreserving moiety.

A method for transporting a biological sample at hypothermic temperatures. The container can be cooled using phase change material and pump fluid through the sample. The fluid can pump through the system at a rate independent of the parameters of the biological sample. A valve can control the rate of flow of the fluid into the biological sample.

Provided herein are methods treating cancer by administering to a recipient mammal reprogrammed T cells. The reprogrammed T cells of the disclosure is produced by a method comprising administering to the donor mammal an effective amount of a composition comprising a plurality of glycopeptides as described herein. Also provided are compositions comprising reprogrammed T cells and methods of producing reprogrammed T cells.

Provided herein are methods for manufacturing CAR-T cell products with high purity of TSCM subsets (>90%), independent of the variations from incoming leukapheresis. In some embodiments, to isolate the CCR7 and CD45RA double positive T cell subset, the processes described herein deplete CD45RO positive cells from leukapheresis and positively enrich for a CD4 and CD8 T cell population to isolation both TSCM and effector memory T cell (TEMRA) subsets, both of which positively express CD45RA and CCR7.

According to one embodiment, a cell detachment method comprising: a detachment step of discharging a liquid used for cryopreservation of cells toward a surface of a culture container in contact with the cells, where the cells are cultured, thereby detaching the cells from the surface; and a recovery step of recovering the detached cells together with the discharged liquid used for cryopreservation.

The present invention relates to a process for preparation and cryopreservation of dental pulp teeth and products thereof resulting in innovative cellular systems useful for therapeutic application based on the mesenchymal stem cells, so called dental pulp stem cells (DPSCs).

The objective of this invention is to provide the most adequate cellular isolates from dental pulp tissue from a tooth of a human subject. Fast expanding populations of DPSCs can be obtained, while maintaining their chromosomal stability, and determined to present the phenotypical and functional characteristics desired of such populations.

In another aspect, the present invention provides a novel and simplified method increasing thSpece viability of the dental tissue during the storing and banking. Also, the isolation of DPSCs from these teeth is improved and herein disclosed.

Therefore, the present invention is in the field of cell-based therapies, regenerative medicine, and optimized processes for obtaining the desired cell-isolates.